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been identified as one of the central components
of the α1 Na/K-ATPase-mediated signaling
transduction (7). In this receptor complex, the
Src SH2 domain binds to the second cytosolic
domain, while Src kinase domain interacts with
the nucleotide binding (N) domain of the α1
subunit. The latter interaction keeps Src in an
inactive state (7). It is important to note that
normal epithelial cells express about a million
α1 Na/K-ATPase (roughly five times of Src).
Thus, the α1 Na/K-ATPase could provide at
least two ways of regulating cellular Src activity.
First, it could bind and keep Src in an inactive
state. Consistently, when knockout of one copy
of α1 gene caused a 20 to 30% reduction in
cellular α1 Na/K-ATPase, it produced more than
2 fold increase in Src and ERK activities in
tissues of α1 +/- mice (8). Second, the formation
of Na/K-ATPase/Src complex provides a
functional receptor for endogenous cardiotonic
steroids (CTS) such as ouabain to regulate
cellular signaling via Src and Src effectors (7,9).
Thus, changes in cellular α1 Na/K-ATPase
would have significant effect on cellular
signaling events induced by either CTS or other
growth factors through Src-related pathways.
Based on the fact that the N domain of α1
subunit binds and inhibits Src, we have recently
made pNaKtide from the N domain of human α1
subunit of Na/K-ATPase (10). Addition of TAT
leader sequence makes it cell permeable.
Moreover, a majority of pNaKtide appears to be
localized in the plasma membrane in cultured
cells. Like the N domain of α1 Na/K-ATPase,
pNaKtide binds and inhibits the Na/K-ATPaseinteracting pool of Src (10).
Consistently,
pNaKtide blocks the formation of receptor
Na/K-ATPase/Src complex, but does not alter
the basal cellular Src activity in cells where the

Cells contain a large pool of non-pumping
Na/K-ATPase that participates in signal
transduction. Here, we show that the
expression of α1 Na/K-ATPase is significantly
reduced in human prostate carcinoma as well
as in several human cancer cell lines. This
down-regulation impairs the ability of Na/KATPase to regulate Src-related signaling
processes.
Supplement of pNaKtide, a
peptide derived from α1 Na/K-ATPase,
reduces activities of Src and Src effectors.
Consequently, these treatments stimulate
apoptosis and inhibit growth in cultures of
human
cancer
cells.
Moreover,
administration
of
pNaKtide
inhibits
angiogenesis and growth of tumor xenograft.
Thus, the new findings demonstrate the in
vivo effectiveness of pNaKtide, and suggest
that the defect in Na/K-ATPase-mediated
signal transduction may be targeted for
developing new anti-cancer therapeutics.
The Na/K-ATPase was originally discovered
as an ion pump that is essential for cell vitality
and provides a means for epithelium to secrete
and/or absorb solutes and nutrients (1,2). Recent
studies have revealed that in addition to pumping
ions across cell membrane, the Na/K-ATPase,
specifically the α1 isoform, conducts many nonpumping functions including scaffolding and
signal transduction. As a signaling protein, it is
involved in the formation of membrane
structures such as tight junction and caveolae
(3,4). Moreover, a large fraction of cellular
Na/K-ATPase is involved in tethering and
regulating multiple protein and lipid kinases as
well as membrane receptors (e.g. Src, HER and
PI3K) in a cell-specific manner (5,6). Recently,
the α1 Na/K-ATPase/Src receptor complex has
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α1 Na/K-ATPase is adequately expressed (10).
Thus, pNaKtide functions like a receptor
antagonist, capable of inhibiting ouabaininduced signal transduction (10). On the other
hand, it also works like the α1 Na/K-ATPase
(11) and is capable of inhibiting Src and Src
effectors in cells where the expression of Na/KATPase is reduced (10).
Src regulates cell proliferation/apoptosis,
migration, and invasion (12,13) and is involved
in the progression of many types of cancers (14).
Once activated by either receptors (e.g., HER
and androgen receptors) or membrane receptorassociated proteins (e.g., G proteins) (15-17),
Src is recruited to cell periphery, focal adhesion
and tight junction where the α1 Na/K-ATPase
resides in a high concentration (18-20).
Previously, we have shown that epithelial cells
actually contain two functionally distinct pools
of Na/K-ATPase and that reduction of cellular
α1 Na/K-ATPase preferentially depletes the Srcinteracting pool of Na/K-ATPase, resulting in an
elevation in cellular activities of Src and Src
effectors (8,11,21). Thus, should the α1 Na/KATPase be down-regulated in cancer cells, this
could contribute to an increase in kinase activity
observed in cancers such as prostate carcinoma.
Conversely, repletion of the α1 Na/K-ATPase or
application of pNaKtide would antagonize the
increase in kinase activity, which could inhibit
tumor growth. To test these hypotheses, we first
assessed the expression of α1 Na/K-ATPase in
prostate carcinomas and established cancer cell
lines, and measured the Na/K-ATPase-mediated
signal transduction focusing on those that are
Src-related. We then tested whether application
of α1 Na/K-ATPase mimetics such as pNaKtide
could attenuate the activities of cellular Src and
Src effectors and inhibit tumor growth.

α1 antibody α6f was obtained from the DSHB at
the University of Iowa. pNaKtide was
synthesized with purity above 95%. All other
chemicals were from Sigma-Aldrich (St. Louis,
MO).
Cell Culture. RWPE-1, DU145, LNCaP, PC-3,
and LLC-PK1 cells were all from American
Type Culture Collection (ATCC) and grown
according to ATCC recommendations. DU145
and PC-3 are prostate cancer cell lines originally
isolated from metastatic sites in brain and bone,
respectively. LNCaP cells recapitulate prostate
cancer progression due to relatively slow growth
and expression of androgen receptor, while
RWPE-1 is a non-tumorigenic human prostate
epithelial cell line. Human umbilical vein
endothelial cells (HUVEC) and aortic
endothelial cells (HAEC) were obtained from
Lonza (Walkersville, MD) and maintained in the
M199 medium supplemented with 10% FBS, 50
μg/ml endothelial cell growth supplement (BD
Biosciences), and 50 μg/ml heparin (BD
Biosciences). The Na/K-ATPase α1-knockdown
TCN23-19 cells were developed from LLC-PK1
cells and maintained as described (11).
Plasmid Constructs and Transient Transfections.
The CMV promoter-driven pEYFP-ND1
construct was generated as described (10).
Transient transfections were performed using
LipofectAMINE 2000 (Invitrogen) according to
the manufacturer's instructions. Expression of
YFP or YFP-tagged proteins was monitored
using an Olympus fluorescence microscope.
Images were processed with SPOT software
Version 4.60 (Diagnostic Instruments).
Immunoblot Analysis. Immunoblot analysis was
performed as described previously (22).
Following the indicated treatment, the cells were
rapidly washed with ice-cold PBS. Then the
cells were lysed in modified ice-cold
radioimmune precipitation assay (RIPA) buffer
containing 1% Nonidet P-40, 1% sodium
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1
mM phenylmethylsulfonyl fluoride, 1 mM
sodium orthovanadate, 1 mM NaF, 10 g/ml
aprotinin, 10 g/ml leupeptin, and 50 mM TrisHCl, pH 7.4. The cell lysates were centrifuged at
14,000 × g for 15 min, and the supernatants were
separated by SDS-PAGE, and transferred to the
Optitran nitrocellulose membranes (Schleicher
and Schuell, Dassel, Germany). The membranes
were blocked and probed with specific
antibodies.
Measurement of Cell Surface and Endocytosed
α1 Na/K-ATPase. The surface expression of the

Experimental Procedures
Materials. Staurosporine was obtained from
Calbiochem. The following antibodies were
obtained from Santa Cruz Biotechnology: Src
(sc-8056), PARP-1 (sc-8007), c-Myc (sc-40),
ERK (sc-94), phospho-ERK (sc-7383) and
GAPDH (sc-20357). Antibodies against
phospho-FAK (Tyr576/577) (3281) and FAK
(3285) were from Cell Signaling Technology.
Antibodies against VEGF (Abcam, ab46154)
and pY418 (Invitrogen, 44-660G) were also
used. HRP-conjugated anti-rabbit and antimouse secondary antibodies were obtained from
Santa Cruz Biotechnology. The monoclonal anti-
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dissolved with detergent, and the OD value was
measured at 570 nm.
Apoptosis Assay. Annexin/PI staining and
TUNEL assay were performed using the
Vybrant Apoptosis Assay Kit (Invitrogen) and
the TUNEL Apoptosis Detection Kit (Upstate),
respectively. Briefly, treated cells were
resuspended and mixed with Alexa Fluor 488
annexin V/PI in the annexin-binding buffer.
Mounted cells were visualized with a Leica
DMIRE2 confocal microscope. To detect
apoptotic cells in xenografted tumor tissues,
TUNEL assay was performed according to the
manufacturer’s instructions. Slides containing
formalin-fixed,
paraffin-embedded
tumor
sections were depariffinized and then washed
with PBS for 30 min at 37°C. After incubation
with proteinase K (Invitrogen), tumor sections
were mixed with TdT end-labeling cocktail
(containing Biotin-dUTP, TdT in TdT buffer) for
60 min at 37°C. After blocking, the tumor
sections were incubated with avidin-FITC
solution for 30 min at 37°C. Washed tumor
sections were further counterstained with PI
solution and visualized with a Leica DMIRE2
confocal microscope.
DU145 Xenograft Tumors in NOD/SCID Mice.
Animal protocols were approved by the
Institutional Animal Care and Use Committee at
the University of Toledo Health Science
Campus. Tumor xenografts were established by
s.c. injection of 5 × 106 DU145 cells into the left
and right flanks of 6-week-old female
NOD/SCID mice (Charles River). Tumor length
(L) and width (W) were measured with calipers
and tumor volume was estimated as V = (L ×
W2)/2. When the tumors reached an average
volume of 100 mm3, mice were s.c. injected with
saline or pNaKtide (at doses of 2 mg/kg and 10
mg/kg body weight) every other day for 5 times.
Immunostaining of α1 Na/K-ATPase and Active
Src. Cells cultured on coverslips were fixed for
15 min with ice-cold methanol, washed with
PBS for three times and then blocked with
Signal Enhancer (Invitrogen). The cells were
then incubated with a mouse anti-Na/K-ATPase
α1 monoclonal antibody (Millipore) or a rabbit
anti-pY418 antibody (Invitrogen) in PBS
containing 1% bovine serum albumin for 1 h at
room temperature. After three washes with PBS,
cells were exposed to AlexaFluor 555conjugated anti-mouse or AlexaFluor 488conjugated anti-Rabbit secondary antibody for 1
h at room temperature, washed and mounted

α1 Na/K-ATPase was measured by biotinylation
using the procedures described before (21,23). In
brief, cultured cells were placed on ice and
rinsed twice with ice-cold PBS containing 1mM
EDTA for 5 min, which opens tight junctions
(23). Then cells were exposed twice to 1.5
mg/mL EZ-Link Sulfo-NHS-SS-Biotin (Pierce)
in biotinylation buffer (10 mM triethanolamine,
150 mM NaCl, pH 9.0) for 25 min at 4 °C.
Unreacted Sulfo-NHS-SS-Biotin was scavenged
by incubation with 100 mM glycine buffer (in
PBS) for 20 min. Cells were then solubilized in
lysis buffer (1% Triton X-100, 150 mM NaCl, 5
mM EDTA, 50 mM Tris, pH 7.5) and cell
lysates were cleared by centrifugation at 14,000g
for 15 min at 4 °C. Supernatants from different
treatment groups (based on equal amount of
protein) were incubated overnight at 4 °C with
streptavidin-agarose beads (Pierce). The beads
were then washed twice with lysis buffer, twice
with high-salt buffer (0.1% Triton X-100, 500
mM NaCl, 5 mM EDTA, 50 mM Tris, pH7.5),
and twice with no-salt wash buffer (10 mM Tris,
pH 7.5). Bound proteins were eluted with
sodium dodecyl sulfate-containing sample buffer
and subject to immunoblot analysis as described
above.
Endocytosis of the α1 Na/K-ATPase was
measured using a pulse-chase strategy.
Biotinylation of cell surface was conducted as
described
above,
and
unreacted
Nhydroxysulfosuccinimidobiotin was quenched
with glycine buffer. Then cells were brought
back to normal culture conditions for 0 or 30
min at 37 oC, allowing biotinylated surface 1
Na/K-ATPase to be endocytosed.
The
endocytosis was terminated by washing cells
with ice-cold PBS. Afterwards, Tris(2carboxyethyl)phosphine
(TCEP, Pierce)
reducing agent (100 mM TCEP in 50 mM Tris,
pH 7.4) was added to cells for 30 min at 4 °C to
clear the remaining cell surface-bound biotin.
Cell lysates in lysis buffer (1% Triton X-100,
150 mM NaCl, 5 mM EDTA, 50 mM Tris, pH
7.5) were collected. Equal amount of cell lysates
(500 µg protein) was incubated with
streptavidin-agarose beads and bound proteins
were analyzed by Western blot.
MTT Assay. MTT assay was performed using the
MTT cell proliferation assay kit (ATCC). In
brief, 6,000 cells/well were cultured overnight,
and then were exposed to different
concentrations of pNaKtide for the indicated
time. Ten µl of MTT reagent was added to each
well for 120 min. The formazan crystal was

3

onto slides. Image visualization was performed
using a Leica DMIRE2 confocal microscope.
Immunohistochemical (IHC) Staining and
Vascularity Analysis. Na/K-ATPase α1 IHC
staining was performed by US Biomax
(Rockville, MD) using A human prostate tissue
microarray (TMA Cat. # PR954, US Biomax),
which contains 36 cases of prostate carcinoma
and 8 cases of normal tissues. In brief, prostate
TMA was depariffinized, hydrated, and
incubated with 3% H2O2 to block endogenous
peroxidase. Then, tissue sections were subjected
to antigen retrieval by using Target Retrieval
Solution (Dako Cytomation) and blocked with
normal horse blocking serum. Tissue sections
were incubated with a mouse monoclonal antiNa/K-ATPase α1 antibody (Millipore) solution
(final concentration 3.3 ng/µl) for 1 hour at room
temperature. Slides were washed and then
incubated with ImmPRESS Reagent anti-Mouse
Ig peroxidase (Vector Laboratories) for 1 hour
followed by incubation with DAB substrate
solution (Dako Cytomation) for 5 min. Slides
were mounted and images were recorded with an
Olympus light microscope. Specific IHC
staining of Na/K-ATPase α1 yields brown color
at site of the target antigen, while Hematoxylin
counterstaining yields blue color in cell nucleus.
Two independent pathologists examined α1
staining intensity and scored each slide three
times as defined: 0, absent; 1, weak; 2,
moderate; 3, strong. A mean score was recorded.
To assess tumor vascularity in the xenograft
tumor tissues, IHC staining of CD31 in tissue
sections was performed as aforementioned. A
goat polyclonal anti-CD31 antibody (Santa Cruz
Biotechnology, sc-1506, final concentration
2ng/µl) and ImmPRESS Reagent anti-goat Ig
peroxidase (Vector Laboratories) were used.
Negative controls were performed by replacing
primary
antibody
with
normal
goat
immunoglobulins. Then, the CD31 positive
regions (in brown) were quantified using ImageJ
1.43 and vascularity density was calculated as
the percent of tumor tissue area occupied by
vessels as described (24).
Analysis of Data. Data are given as the mean ±
SEM. Differences of formed tumors in response
to saline or pNaKtide were calculated with chisquare test. One-way ANOVA test was used to
test the significance in tumor weights and tumor
volumes. Statistical significance of data from all
other experiments was determined by Student’s
t-test. A p value of <0.05 was considered to be
significant.

Results
Down-regulation of α1 Na/K-ATPase in prostate
cancer. As depicted in Figs. 1A and B, the
expression of α1 Na/K-ATPase is significantly
reduced in human prostate carcinoma (PCa) as
measured by IHC staining. While most of the
control samples exhibited moderate to strong
staining, more than 50% of PCa samples (20
samples out of a total of 36) had a weak staining.
Moreover, about 11% of samples (4 out of a
total of 36) were actually scored absent for α1
Na/K-ATPase. To verify these findings and to
establish an in vitro model for further
investigation, we conducted the following
studies in three human prostate cancer cell lines
that exhibit different metastatic potentials (25).
Normal human prostate epithelial RWPE-1 cells
and LLC-PK1 cells, a non-cancerous renal
epithelial cell line extensively used in our prior
studies of Na/K-ATPase-mediated signal
transduction (7,22), were used as controls. As
shown in Fig. 1C, significant reduction in the
total cellular α1 Na/K-ATPase was noted in
DU145 and PC-3 cell lysates. Because the α1
Na/K-ATPase regulates mainly the plasma
membrane, not cytoplasmic, pool of Src, we
immunostained these cells with anti-α1 antibody
and examined the cellular distribution of α1
Na/K-ATPase. As depicted in Fig. 2A, the α1
subunit mainly resided in the plasma membrane
in control cell lines. This pool of 1 Na/KATPase is significantly reduced in cancer cell
lines. Quantitative analyses using line scanning
reveal a reduction of about 15%, 50% and 75%
in the plasma membrane area across the LNCaP,
DU145 and PC-3 cells, respectively (Fig. 2B).
These reductions were further confirmed by
surface biotinylation assays (Fig. 2D).
Interestingly, high level of diffused and vesicular
α1 staining relative to the plasma membrane
signal was noted in DU145 and PC-3 cells (Fig.
2C) after increasing the laser intensity. These
findings suggest an increased endocytosis of α1
Na/K-ATPase in these cells. To further test this,
a pulse-chase experiment was performed to
directly measure the endocytosed α1 in DU145
cells. Surface-biotinylated cells were brought
back to normal culture condition for different
times, and then surface-bound biotin was cleared
using TCEP. The remaining biotinylated
intracellular pool of α1 was analyzed. Because a
large number of RWPE-1 cells detached from
culture dish during TCEP treatment, LLC-PK1

4

cells were used as a control. As shown in Fig.
2E, there was no endocytosed α1 detected at 0
min, suggesting that TCEP cleavage was
complete. After recovery for 30 min, much more
(about 3-times) α1 was endocytosed in DU145
than that in LLC-PK1 cells. Considering the
difference in the membrane α1 amount in these
two cell lines (Fig. 2B and 2D), the α1
endocytosis per 30 min in DU145 cells could be
9-10 times of that in LLC-PK1 cells.
As depicted in Fig. 3A, the amount of active
Src or Src family kinases was significantly
elevated in human cancer cells.
Because
reduction of the α1 preferentially affects the Srcinteracting pool of Na/K-ATPase (11,21), this
increase in Src activity could be due to the
down-regulation of α1 Na/K-ATPase in these
cells. If this is a case, it is likely that addition of
α1 mimetic peptide would be able to inhibit Src
and then cancer cell growth. To test this
possibility, we transfected DU145 cells with
YFP-ND1 and evaluated its effect on cell
growth. The ND1 peptide is derived from the N
domain of 1 subunit (residues 379-435), and
binds and inhibits Src (10). As depicted in Fig.
S1A, the expression of YFP-ND1 was detected
as early as 6 h post transfection and peaked at 24
h in DU145 cells.
Notably, a significant
decrease in the percentage of cells with YFP
fluorescence was observed after 36 h in the
YFP-ND1-transfected, but not YFP-transfected,
cells. Moreover, a large number of YFP-ND1expressing cells rounded up and detached from
the dish (Fig. S1A). When Trypan Bluenegative cells were counted, expression of YFPND1 caused more than a 40% decrease in the
number of cells (Fig. S1B). Taken together,
these findings indicate that the expression of
ND1 has drastic effects on cell viability.

(Fig. 3B). Finally, pNaKtide was also capable of
reducing the expression of c-Myc (Fig. 3B) that
is known to play an important role in prostate
cancer development.
These data together
indicate that pNaKtide could be used to attenuate
the elevated activities of Src, Src effectors and cMyc in cancer cells. It is important to note that
pNaKtide is apparently specific to the α1interacting pool of Src because while pNaKtide
had no effect on basal Src activity in LLC-PK1
cells [Fig. 2A and Ref (10)], it did produce a
significant inhibition of Src in LLC-PK1derived TCN23-19 cells (Fig. S2) where the
Na/K-ATPase-interacting pool of Src is freed by
90% knockdown of the α1 subunit (11).
Effects of pNaKtide on cell growth.
Src is known to play an important role in
regulating cell growth and apoptosis (12). We
therefore evaluated the growth inhibitory effects
of pNaKtide using MTT analysis. A timedependent growth inhibition in DU145 cells was
presented in Fig. 4A. It is important to note that
pNaKtide also affected cell viability, which is
apparent at higher concentrations (e.g. 1 and 5
M).
When dose-dependent effects were
measured in all three cancer cell lines, we found
that LNCaP cells were most resistant to
pNaKtide, whereas PC-3 cells were highly
sensitive (Fig. 4B). The EC50 value of pNaKtide
was 100 nM, 5 µM and 20 µM in PC-3, DU145
and LNCaP cells, respectively. As a control, we
repeated this set of experiments with pC1 (10).
Like pNaKtide, pC1 is tagged with TAT leader
sequence, and it is also distributed in the cell
membrane (data not shown). We found that pC1
did not have any inhibitory effect in the MTT
assay up to 20 µM.
Because pNaKtide affects cell viability, we
tested whether pNaKtide stimulates apoptosis in
DU145 cells using the following two sets of
experiments. Staurosporine was used as a
positive control. First, we measured the effect of
pNaKtide on the cleavage of poly (ADP-ribose)
polymerase (PARP) (26,27). As shown in Fig.
5A, like staurosporine (STS), pNaKtide (1 and 5
µM) stimulated PARP cleavage in DU145 cells.
To verify the apoptotic effect of pNaKtide,
annexin V/PI staining were performed. Like
staurosporine, pNaKtide produced a clear
membrane staining of annexin V without nuclear
PI staining (Fig. 5B).

pNaKtide attenuates activities of Src and Src
effectors. In view of the above findings, we next
tested whether the ND1-derived pNaKtide can
inhibit activities of Src and Src effectors in
human cancer cells. As shown in Fig. 3A,
pNaKtide had no effect on basal Src activity in
LLC-PK1 cells as we previously reported (10).
However, it caused a significant inhibition of the
membrane pool of Src in all three cancer cell
lines. To confirm this finding, cell lysates from
control and pNaKtide-treated DU145 cells were
subjected to Western blot. As depicted in Fig.
3B, pNaKtide inhibited Src in DU145 cells.
Moreover, pNaKtide inhibited known Src
effectors such as FAK and ERKs in DU145 cells

pNaKtide Inhibits DU145 Xenograft Growth.
Because the above in vitro studies indicate that
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pNaKtide can inhibit Src/FAK/ERK and c-Myc
pathways in human prostate cancer cells, we
tested whether it would inhibit the tumor
xenograft growth in vivo. DU145 cells were
chosen for the test because their sensitivity to
pNaKtide is between PC-3 and LNCaP cells. In
the first set of studies, cells were treated with 1
µM pC1 or pNaKtide for 60 min and washed.
Afterwards, 5 × 106 control peptide or
pNaKtide-treated Trypan Blue-negative DU145
cells were injected subcutaneously into 4-6
week-old NOD/SCID mice. We found that this
treatment resulted in a significant reduction in
tumor weight in vivo (tumor weight: pC1, 1.2 ±
0.2 g, n=6, vs. pNaKtide, 0.6 ± 0.2 g, n=6;
p<0.01) after 45 days. However, this regimen of
treatment is much less effective in inhibiting
tumor growth than that of repeated dosing (see
next paragraph).
To test whether pNaKtide can reduce the
growth or cause regression of an existing tumor,
we used three groups of 4-6-week old
NOD/SCID
mice
and
injected
them
subcutaneously with 5 × 106 DU145 cells. The
treatment with pNaKtide (in saline) or vehicle
was initiated after the tumors reached an average
volume of 100 mm3. As depicted in Figs. 6A, B
and C, pNaKtide treatment produced a dosedependent inhibition of tumor growth. When 10
mg/kg pNaKtide was administered once every
two days for five times, it resulted in over 75%
inhibition in both tumor volume (Fig. 6D) and
weight (Fig. 6B) even after stopping
administration of pNaKtide for more than ten
days. Moreover, half of tumors regressed after
pNaKtide treatment and were not detected in
final necropsy (Fig. 6B). Interestingly, while
two out of seven mice in the control group
showed severe metastasis, none was detected in
pNaKtide-treated groups.
To test whether pNaKtide treatment affects
Src expression and Src activity, we measured
total Src and Src Y418 phosphorylation in the
xenograft tumor homogenates. Consistent with
the observation in cultured cells (Fig. 3),
significant inhibition of Src was found in
pNaKtide-treated tumor homogenates (Fig. 7A).
However, pNaKtide treatment had no effect on
the amount of total Src.
Finally, we performed Hematoxylin & Eosin
(H&E) staining of DU145 xenograft tumors. As
depicted in Fig. 7B, untreated tumors showed
compact cell distribution patterns with dark blue
nuclear staining in the vehicle group, suggesting
that these tumor cells were highly proliferative.

Accordingly, there were some cells with
prominent nucleoli under stages of mitosis
(arrowheads in Fig. 7B). Treatment with
pNaKtide resulted in a decrease in cell
population and cell division. In addition, more
TUNEL-positive cells were found in pNaKtidetreated tumors than that in control groups (Fig.
7C).
Inhibition of tumor angiogenesis by pNaKtide.
Tumor growth and metastasis is highly
dependent on angiogenesis (28). Interestingly,
when tumors were collected from both control
and pNaKtide-treated mice, we noticed that
tumors in the pNaKtide-treated group were
much paler than those from the control mice,
suggesting that pNaKtide treatment might inhibit
angiogenesis. To verify, we first assessed the
effect of pNaKtide on the proliferation of
cultured human endothelial cells since
endothelial cell proliferation is the prerequisite
of angiogenesis. As shown in Fig. 8A, pNaKtide
inhibited the proliferation of both HUVEC and
HAEC cells in a dose-dependent manner. To
further test the ability of pNaKtide to inhibit in
vivo angiogenesis, tumors from control and
pNaKtide-treated animals were immunostained
with an antibody against CD31 to identify
vessels. The vessel density of tumors from
control mice was about 10% and pNaKtide
treatment reduced the density to about 2.5%
(Fig. 8B). Moreover, when the production of
vascular endothelial growth factor (VEGF, an
angiogenic factor) was measured in tumor
homogenates, we found that pNaKtide treatment
produced more than 50% reduction in total
VEGF (Fig. 8C). Taken together, these findings
indicate that pNaKtide inhibits tumor
angiogenesis.

Discussion
In this report, we show that the plasma
membrane pool of α1 Na/K-ATPase is
significantly reduced in prostate cancer cells. We
further demonstrate that supplement of the α1
mimetic peptide (e.g., ND1 or pNaKtide)
decreases activities of Src and Src effectors and
consequently inhibits cancer cell growth.
Furthermore, administration of pNaKtide
potently inhibits the angiogenesis, stimulates
apoptosis, and reduces the xenografted tumor
size in the NOD/SCID mice. These conclusions
and other important issues are further discussed.
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counter regulation of Src and other growthpromoting pathways, especially in cellular
structures such as tight junctions and adhesions
where the Na/K-ATPase is highly concentrated
in normal epithelial cells. This could occur
when cellular Src is activated by steroid
hormone/receptor interaction (40,41) or other
factors such as increased activity of HER (42).
Finally, increases in Src activity due to the
down-regulation of α1 could potentiate VEGF
production and then promote angiogenesis.
Needless to say, the potential role of Na/KATPase in control of tumor growth needs to be
further tested in animal models.
The Na/K-ATPase as a target for
developing novel anti-cancer therapeutics: To
our knowledge, this is the first report to show
that α1 Na/K-ATPase mimetic peptides are
effective in inducing apoptosis in prostate cancer
cells (Fig. 5). Moreover, two different sets of
experiments demonstrate that pNaKtide is highly
effective in blocking the growth of DU145
xenograft in vivo.
First, we found that
pretreatment of DU145 cells with pNaKtide
caused a significant reduction in tumor size.
Although it is unlikely that the activity of
pNaKtide loaded into DU145 cells during one
hour exposure would last for 45 days in vivo, its
effects on cell growth during the first few days
could produce this reduction in tumor size. This
mode of action has been demonstrated with other
compounds (43). Second, we found that repeated
dosing (once every two days for a total of five
times) was more effective in reducing tumor size
than that of one hour exposure. Moreover,
repeated dosing appears to be capable of
inducing tumor regression and preventing tumor
metastasis. Of course, these effects need to be
further verified.
Mechanistically,
pNaKtide
stimulates
apoptosis, inhibits cell growth, and decreases
tumor angiogenesis (Figs. 4 and 8). Some of
these effects are likely related to the Src
inhibitory action of pNaKtide.
However,
pNaKtide is unique in the way it regulates
cellular Src. First, pNaKtide is not an ATP
mimetic and thus works differently from this
class of small molecular Src inhibitors (44-47).
Second, it is derived from a widely expressed
endogenous protein (10). Third, a majority of
pNaKtide appears to be localized in the plasma
membrane (10) where the active Src resides.
This action mechanism explains why only
marginal cellular Src activity is inhibited by
pNaKtide (Fig. 3) in normal epithelial cells,

A potential role of Na/K-ATPase in
regulation of tumor growth: A decrease in α1
Na/K-ATPase expression has been noted in
several human cancers including pancreatic (29),
colorectal (30), bladder (31) and kidney (32).
Moreover, prior studies have also documented
the down-regulation of β1 subunit of Na/KATPase in several kidney cancer cell lines (33).
We report here a significant reduction in α1
Na/K-ATPase in human prostate carcinoma as
well as in highly metastatic prostate cancer cell
lines including DU145 and PC-3. The most
significant reduction in α(over 50%) was
detected in the plasma membrane of these cells
(Figs. 2A, 2B and 2D). Moreover, we observed
an increased endocytosis of α1 Na/K-ATPase in
DU145 cells (Fig. 2E). Thus, post-translational
regulation may play an important role in the
down-regulation of α1 Na/K-ATPase in these
cells.
Because prostate cancer cells, in general, do
not need as much Na/K-ATPase to pump as do
the normal epithelial cells, the observed downregulation of 1 Na/K-ATPase might be
expected.
However, recent studies have
revealed that the α1 Na/K-ATPase has many
non-pumping functions that could play an
important role in regulation of cell migration and
growth. For example, the formation of tight
junction in epithelia requires the expression of
Na/K-ATPase (34). Moreover, the β subunit is
known to play an important role in cell/cell
adhesion as well as cell/matrix interaction (35).
Interestingly, repletion of β1 subunit appears to
be sufficient to reduce the migration and tumor
formation of kidney cancer cells (36).
Furthermore, we have recently demonstrated an
important role of Na/K-ATPase α1 subunit in
regulation of cellular kinase activity through its
interaction with c-Src in the plasma membrane
(7,8,11,37). Therefore, we suggest that the
reduction in the plasma membrane α1 could
affect the growth of tumor in several ways.
First, the down-regulation of α1 Na/K-ATPase
might make it less effective for Na/K-ATPase to
interact with and then inhibit cellular Src. This
would increase basal Src and FAK activity and
consequently
promote
epithelial
cell
proliferation, migration and invasion (34,38,39).
Consistently, we found that metastatic prostate
cancer cells are highly sensitive to the addition
of the Na/K-ATPase α1 mimetics, including
ND1 (Fig. S1) and pNaKtide (Fig. 4). Second, a
decrease in the plasma membrane Na/K-ATPase
α1 would impair the ability of cells to provide a
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whereas small-molecule ATP mimetic produced
a complete inhibition (44).
This is also
consistent with the finding that pNaKtide is less
effective in inhibiting the growth of LNCaP cells
where a large pool of α1 Na/K-ATPase is
expressed in the plasma membrane. On the
other hand, pNaKtide becomes highly effective
for more metastatic cells such as DU145 and
PC-3 where the plasma membrane pool of Na/KATPase is significantly reduced (Fig. 2). Thus,
the effect of pNaKtide appears to be highly
selective.
Since peptides are normally vulnerable to
peptidase degradation, more studies are needed

to further characterize the stability of pNaKtide
in vivo. Absorption and metabolism of pNaKtide
in whole animals remain to be assessed. It would
also be important to characterize the distribution
and stability of pNaKtide in tumor samples.
Nevertheless, our studies here clearly
demonstrate the anticancer efficacy of pNaKtide
in vivo. Finally, it has not escaped our notice
that increased expression of the Na/K-ATPase
α1 could present another strategy to target the α1
Na/K-ATPase-mediated signal transduction in
cancer cells. However, effective compounds
remain to be discovered and tested.
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FIGURE LEGENDS
Figure 1. Downregulation of α1 Na/K-ATPase in prostate cancer cells. A, α1 expression patterns
in paired human normal prostate tissue (left in A) and carcinoma (right in A). Human tissue arrays
were immunostained with monoclonal antibody against α1 (in brown). Hematoxylin was used for
counterstaining of cell nucleus (in blue). B, α1 staining score in prostate tissues. Staining intensity was
scored as absent (0), weak (1), moderate (2), or strong (3). Two independent pathologists scored each
slide three times. C, Expression of Na/K-ATPase α1 subunit in cultured cells. Equal amount of whole
cellular proteins (20 µg) from confluent cells were subject to Western blot analysis with the anti-α1
antibody. The upper panel shows representative blots of α1 and GAPDH, and the lower panel shows
the quantification data of α1 intensity from four independent experiments. *, p<0.05; **, p<0.01.
Figure 2. Decreases in surface expression of α1 Na/K-ATPase in prostate cancer cells. A, Cellular
distribution of α1 Na/K-ATPase. The fixed cells were immunostained with anti-α1 antibody and
visualized (in Red) with a Leica DMIRE2 confocal microscope. Representative images from four
independent experiments are shown. The scale bar represents 5 µm. B, Line scan quantitation of α1
staining intensity across the cell membrane. The α1 intensity was line-scan quantified using ImageJ. X
axis is defined as distance (in pixel unit) from cell membrane where the highest α1 staining intensity
is. Y axis is the arbitrary unit of quantified staining intensity within each pixel unit. Thirty individual
cells from three separate experiments were used to collect these data. C, Cellular distribution of α1 in
DU145 and PC-3 cells after higher intensity laser was applied. The scale bar represents 8 µm. D, Cell
surface α1 in cultured cells. Biotinylated cell surface proteins were analyzed for α1 by Western blot.
Representative blots from three independent experiments are shown. E, Endocytosed α1 in cultured
cells. The upper panel depicts a typical immunoblot of biotinylated α1 Na/K-ATPase after 0 and 30
min recovery. The assays were conducted as described in “Experimental Procedures”. Quantified data
from three independent experiments are shown in the lower panel as relative to LLC-PK1. p<0.05;
**, p<0.01.
Figure 3. Effects of α1 mimetics on Src signaling in DU145 cells. A, Active Src in control or
pNaKtide-treated (1 µM for 1 h) cells. Cells on coverslips were fixed with ice-cold methanol, then
immunostained using anti-pY418 antibody. Fluorescence of Src pY418 was visualized (in Green)
with a Leica DMIRE2 Confocal Microscope. Representative images from three separate experiments
are shown. The scale bar represents 5 µm. B, Regulation of Src and Src effectors by pNaKtide.
DU145 cells were exposed to pNaKtide at indicated concentrations for 1 h. Cell lysates were analyzed
for Src, ERK, and FAK phosphorylation as well as c-Myc by Western blot. Representative blots from
three independent experiments are shown.
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Figure 4. Effect of pNaKtide on DU145 cell proliferation. Cells were seeded in 96-well plates and
exposed to pNaKtide as the function of times (A) or doses (B). MTT assay was performed according
to the instructions from ATCC. n=4.
Figure 5. Induction of apoptosis by pNaKtide in DU145 cells. A, PARP cleavage induced by
pNaKtide. The DU145 cells were exposed to pNaKtide or 0.5 µM staurosporine (STS) for 24 h. The
attached and detached cells from the culture media were collected and analyzed for PARP by Western
blot. Representative blots from three independent experiments are shown. B, Annexin V/PI staining of
DU145 cells in the absence or presence of pNaKtide. Upon treatment, DU145 cells were stained with
annexin V and counterstained with PI using the Vybrant Apoptosis Kit. Annexin V (in green) and PI
(in red) were visualized using a Leica DMIRE2 confocal microscope. Representative images of four
independent studies are shown. The scale bar represents 8 µm.
Figure 6. Effect of pNaKtide on the growth of DU145 xenografts in NOD/SCID mice. DU145
cells (5  106) were s.c. injected in the flank of NOD/SCID mice. After mean tumor volume reached
100 mm3, mice were injected with saline or pNaKtide at a dose of 2 mg/kg or 10 mg/kg. A, Average
body weight of the NOD/SCID mice after administration of pNaKtide. B, Tumor formation in
NOD/SCID mice. The average tumor weight values were from 4 and 6 tumors of 2 mg/kg and 10
mg/kg pNaKtide-treated groups, respectively. C, Mice bearing xenograft tumors. Arrowheads
identified the location of the tumors. D, Growth of DU145 xenograft tumors in NOD/SCID mice
treated with saline or pNaKtide. *, p<0.05; **, p<0.01.
Figure 7. Characterization of xenograft tumors. Fourteen tumors in saline group and six tumors in
10 mg/kg pNaKtide group were analyzed herein. A, Effects of pNaKtide on Src. Tumor homogenates
from saline and pNaKtide groups were analyzed for total Src and Src pY418 by Western blot.
Quantitative data were collected as the pY418/Src ratio from tumor samples. B, H&E staining of the
formalin-fixed, paraffin-embedded xenograft tumors. Original magnifications, × 600. Arrowheads
indicate cells in mitosis. C, TUNEL assay of xenograft tumors. TUNEL assay was performed using
the TUNEL Apoptosis Detection Kit and percent of TUNEL-positive cells was quantified. **, p<0.01.
Figure 8. Effects of pNaKtide on angiogenesis. A, Inhibition of endothelial cell proliferation by
pNaKtide. HUVEC / HAEC cells cultured in 12-well plates were exposed to pNaKtide at indicated
concentrations for 72 h. Then, Trypan Blue-negative cells were counted. Data from four independent
experiments were collected. B, Vessel density of xenograft tumors. IHC staining of CD31 in the
formalin-fixed, paraffin-embedded xenograft tumors (14 in saline group and 6 in 10 mg/kg pNaKtide
group) was performed to identify the vessels. Then, the vessel density was calculated as the percent of
tumor area occupied by vessels. C, Expression of VEGF in tumor homogenates. VEGF levels in the
saline or pNaKtide-treated tumors were evaluated by Western blot using the anti-VEGF antibody. *,
p<0.05; **, p<0.01.
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